This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gerber, H.-P. Articles by Ferrara, N. Search for Related Content PubMed PubMed Citation Articles by Gerber, H.-P. Articles by Ferrara, N. Related Collections Therapeutics and Targets Therapeutics and Targets: Pharmacology and Toxicology

Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies

Departments of Molecular Oncology, Genentech, Inc., South San Francisco, California

Requests for reprints: Hans-Peter Gerber, Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-8244; Fax: 650-225-6443; E-mail: gerberhp{at}gene.com.

Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti–vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its murine equivalent A4.6.1. These studies found that single-agent therapy with bevacizumab/A4.6.1 resulted in tumor growth inhibition of 20 different human tumor cell lines (13 tumor types) implanted into nude mice irrespective of the route of administration or tumor location. Several of these studies also observed significant inhibition of tumor metastases. Various studies have examined the feasibility of combining anti-VEGF therapy with cytotoxic or biological agents. Combining bevacizumab/A4.6.1 with doxorubicin, topotecan, paclitaxel, docetaxel, or radiotherapy resulted in additive or synergistic tumor growth inhibition. Changes in vascular functions were frequently reported, including decreased vessel diameter, density, and permeability in response to treatment. A reduction in interstitial fluid pressure was also observed. In some studies, these improvements resulted in an increase in intratumoral uptake of chemotherapy, implying that the most effective use of anti-VEGF therapy is in combination with chemotherapy. Alternatively, combination treatment with radiation increased tumor oxygenation and tumor growth inhibition. Interestingly, anti-VEGF therapy has also been reported to reduce the development of ascites in ovarian mouse models. Finally, safety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally well tolerated with no unexpected adverse events.

Key Words: bevacizumab • rhuMAb VEGF • pharmacology • pharmacodynamics

This article has been cited by other articles:

				J. Iwasaki and S.-i. Nihira Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers Jpn. J. Clin. Oncol., June 16, 2009; (2009) hyp062v1. [Abstract] [Full Text] [PDF]

				D. J. Freeman, T. Bush, S. Ogbagabriel, B. Belmontes, T. Juan, C. Plewa, G. Van, C. Johnson, and R. Radinsky Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor Mol. Cancer Ther., June 1, 2009; 8(6): 1536 - 1546. [Abstract] [Full Text] [PDF]

				N. Schicher, V. Paulitschke, A. Swoboda, R. Kunstfeld, R. Loewe, P. Pilarski, H. Pehamberger, and C. Hoeller Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma Clin. Cancer Res., May 15, 2009; 15(10): 3495 - 3502. [Abstract] [Full Text] [PDF]

				D. K. Shah, B. S. Shin, J. Veith, K. Toth, R. J. Bernacki, and J. P. Balthasar Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 580 - 591. [Abstract] [Full Text] [PDF]

				K Engels, A du Bois, P Harter, A Fisseler-Eckhoff, F Kommoss, R Stauber, M Kaufmann, V Nekljudova, and S Loibl VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection J. Clin. Pathol., May 1, 2009; 62(5): 448 - 454. [Abstract] [Full Text] [PDF]

				K. Kolinsky, B.-Q. Shen, Y.-E Zhang, J. Kohles, U. Dugan, T. F. Zioncheck, D. Heimbrook, K. Packman, and B. Higgins In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models Mol. Cancer Ther., January 1, 2009; 8(1): 75 - 82. [Abstract] [Full Text] [PDF]

				K. KOLINSKY, Y.-E ZHANG, U. DUGAN, D. HEIMBROOK, K. PACKMAN, and B. HIGGINS Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts Anticancer Res, January 1, 2009; 29(1): 91 - 98. [Abstract] [Full Text] [PDF]

				M. S. Morrison, S.-A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy J. Nucl. Med., January 1, 2009; 50(1): 116 - 122. [Abstract] [Full Text] [PDF]

				S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al. Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model Clin. Cancer Res., December 1, 2008; 14(23): 7781 - 7789. [Abstract] [Full Text] [PDF]

				D. Zorzi, Y. S. Chun, D. C. Madoff, E. K. Abdalla, and J.-N. Vauthey Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases Ann. Surg. Oncol., October 1, 2008; 15(10): 2765 - 2772. [Abstract] [Full Text] [PDF]

				R. Hlushchuk, O. Riesterer, O. Baum, J. Wood, G. Gruber, M. Pruschy, and V. Djonov Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation Am. J. Pathol., October 1, 2008; 173(4): 1173 - 1185. [Abstract] [Full Text] [PDF]

				G. Nasti, A. Ottaiano, V. Rosario Iaffaioli, M. Berretta, and P. Delrio Trials on Preoperative Chemotherapy in Resectable Colorectal Liver Metastases Need Prospective Evaluation of Predictive Factors of Response J. Clin. Oncol., August 1, 2008; 26(22): 3812 - 3813. [Full Text] [PDF]

				M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]

				S. K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153. [Abstract] [Full Text] [PDF]

				A. Dowlati, R. Gray, A. B. Sandler, J. H. Schiller, and D. H. Johnson Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study Clin. Cancer Res., March 1, 2008; 14(5): 1407 - 1412. [Abstract] [Full Text] [PDF]

				Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]

				A. Ocana and A. Pandiella Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970. [Abstract] [Full Text] [PDF]

				M. Calvani, D. Trisciuoglio, C. Bergamaschi, R. H. Shoemaker, and G. Melillo Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells Cancer Res., January 1, 2008; 68(1): 285 - 291. [Abstract] [Full Text] [PDF]

				J.-L. Li, R. C.A. Sainson, W. Shi, R. Leek, L. S. Harrington, M. Preusser, S. Biswas, H. Turley, E. Heikamp, J. A. Hainfellner, et al. Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo Cancer Res., December 1, 2007; 67(23): 11244 - 11253. [Abstract] [Full Text] [PDF]

				W. B. Nagengast, E. G. de Vries, G. A. Hospers, N. H. Mulder, J. R. de Jong, H. Hollema, A. H. Brouwers, G. A. van Dongen, L. R. Perk, and M. N. Lub-de Hooge In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft J. Nucl. Med., August 1, 2007; 48(8): 1313 - 1319. [Abstract] [Full Text] [PDF]

				P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy Clin. Cancer Res., July 1, 2007; 13(13): 3942 - 3950. [Abstract] [Full Text] [PDF]

				H.-P. Gerber, X. Wu, L. Yu, C. Wiesmann, X. H. Liang, C. V. Lee, G. Fuh, C. Olsson, L. Damico, D. Xie, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies PNAS, February 27, 2007; 104(9): 3478 - 3483. [Abstract] [Full Text] [PDF]

				B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				B. I. Rini and W.K. Rathmell Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s. [Abstract] [Full Text] [PDF]

				B. D. Zeitlin, E. Joo, Z. Dong, K. Warner, G. Wang, Z. Nikolovska-Coleska, S. Wang, and J. E. Nor Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. Cancer Res., September 1, 2006; 66(17): 8698 - 8706. [Abstract] [Full Text] [PDF]

				E. A. Sausville Respecting cancer drug transportability: a basis for successful lead selection. J Natl Cancer Inst, August 16, 2006; 98(16): 1098 - 1099. [Full Text] [PDF]

				B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129. [Abstract] [Full Text] [PDF]

				I. Sakimoto, K. Ohta, T. Yamazaki, S. Ohtani, H. Sahara, F. Sugawara, K. Sakaguchi, and M. Miura {alpha}-Sulfoquinovosylmonoacylglycerol Is a Novel Potent Radiosensitizer Targeting Tumor Angiogenesis Cancer Res., February 15, 2006; 66(4): 2287 - 2295. [Abstract] [Full Text] [PDF]

				W.-C. Liang, X. Wu, F. V. Peale, C. V. Lee, Y. G. Meng, J. Gutierrez, L. Fu, A. K. Malik, H.-P. Gerber, N. Ferrara, et al. Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF J. Biol. Chem., January 13, 2006; 281(2): 951 - 961. [Abstract] [Full Text] [PDF]